Format

Send to

Choose Destination
Am J Epidemiol. 2018 Nov 1;187(11):2397-2404. doi: 10.1093/aje/kwy129.

Can E-Cigarettes and Pharmaceutical Aids Increase Smoking Cessation and Reduce Cigarette Consumption? Findings From a Nationally Representative Cohort of American Smokers.

Author information

1
Cancer Prevention Program, Moores Cancer Center, University of California, San Diego, La Jolla, California.
2
Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, California.
3
Division of Epidemiology, Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, California.
4
Division of Health Policy, Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, California.
5
Stanford Prevention Research Center, Stanford University, Palo Alto, California.
6
Division of Behavioral Medicine, Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, California.

Abstract

Many smokers believe that electronic nicotine delivery systems (ENDS) and pharmaceutical cessation aids can help them quit smoking or reduce cigarette consumption, but the evidence for e-cigarettes to aid quitting is limited. Examining 3,093 quit attempters in the nationally representative US Population Assessment of Tobacco and Health (PATH) Study, using data from 2013-2015, we evaluated the influence of ENDS and pharmaceutical cessation aids on persistent abstinence (≥30 days) from cigarettes and reduced cigarette consumption, using propensity score matching to balance comparison groups on potential confounders and multiple imputation to handle missing data. At PATH Wave 2, 25.2% of quit attempters reported using ENDS to quit during the previous year, making it the most popular cessation aid in 2014-2015. More quit attempters were persistently cigarette abstinent than were persistently tobacco abstinent (15.5% (standard error, 0.8) vs. 9.6% (standard error, 0.6)). Using ENDS to quit cigarettes increased the probability of persistent cigarette abstinence at Wave 2 (risk difference (RD) = 6%, 95% confidence interval (CI): 2, 10), but using approved pharmaceutical aids did not (for varenicline, RD = 2%, 95% CI: -6, 13; for bupropion, RD = 4%, 95% CI: -6, 17; for nicotine replacement therapy, RD = -3%, 95% CI: -8, 2). Among quit attempters who relapsed, ENDS did not reduce the average daily cigarette consumption (cigarettes per day, -0.18, 95% CI: -1.87, 1.51).

PMID:
29955810
PMCID:
PMC6211241
DOI:
10.1093/aje/kwy129
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center